Eli Lilly's Jaypirca receives FDA approval for first-line treatment of certain leukemia and lymphoma cases
The U.S. Food and Drug Administration (FDA) has granted Eli Lilly’s drug Jaypirca an additional indication as a first-line therapy for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who do not have the 17p deletion, a genetic marker associated with poor prognosis in these diseases. Jaypirca is a non-covalent Bruton's tyrosine kinase (BTK) inhibitor. This new indication expands its use beyond previously approved applications and highlights its potential as an effective treatment option for patients without high-risk features like the 17p deletion, offering clinicians more flexibility in managing these blood cancers. The approval is based on clinical trial data demonstrating Jaypirca's efficacy and safety profile in this patient population. This development could enhance Eli Lilly’s market position within oncology drug therapies.
Tickers: $LLY